PRAVIC & PRAVIC Extension

Innovative recombinant proteins with immune modulatory and antitumor activities - Focus on therapeutic MAbs

PRAVIC & PRAVIC Extension est accrédité par Lyonbiopôle

Identity card

Global budget: 5850 k€

Public funding: 2284 k€

Public funders: Conseil général de Rhône, FEDER Rhône-Alpes, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Oséo / BPI France (except FUI), Région Rhône-Alpes

Call for projects: FUI (FUI AAP0)

Year start: 2005

Completed project (2009-09)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Human Medicines, Medical Technologies

Application fields: Autoimmune diseases, Oncology

Technological approaches / Keywords: Biologics, Biomanufacturing, Functional Screening / Drug discovery, Immunotherapy

Stage of development at the beginning of the project: Basic research

Abstract

Treatments for leukaemia and lymphoma still pose a challenge as five-year survival rates remain low. For instance, rituximab has allowed enhanced response rates and prolonged survival in a majority of subtypes of B-cell lymphomas. However the curability of some lymphoma subtypes has not been modified by rituximab. Alemtuzumab tolerance profile has also limited its extensive administration. There still remains a large unmet medical need in hematological malignancies. The projects PRAVIC PRAVIC Extension aimed to generate innovative products to fight cancers. 


Objectives

The permanent increase of the oncology pipelines results of scientific and technological improvements such as - Identification of therapeutic targets, - Development of new therapeutic mechanisms, - Improvements in MAb design, - Progress in the production of biologics, - Advances in preclinical and toxicity studies.    PRAVIC objectives were : - The validation of targets (IL-6, CD19 and CD5), - The discovery of engineered MAbs against each target, - The establishment of the proof of concept in vitro and in vivo,  - The set up USP bioprocess, - Intellectual property generation.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

In collaboration with Vaccinex, OPi has generated a high-affinity fully human anti IL-6 MAb licensed to GSK in 2008. One patent has been applied for. iDD biotech anti CD19 MAbs are the next-generation, humanized, Fc optimized MAbs with a wide range of clinical. Three patents have been applied for iDD biotech anti CD19 MAb. The CD5 antigen is an attractive target for oncology and antibody based active and passive immunotherapy.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte